Otsuka

Hormones in the brain concept
#European Commission #Lundbeck #Neuroscience #Otsuka #Schizophrenia

Brexpiprazole’s EU approval extended to include adolescents

The European Commission (EC) has approved Otsuka’s Rxulti (brexpiprazole) for the treatment of schizophrenia in adolescents aged 13 years and older.  The drug was previously approved in the European Union in 2018 for the treatment of schizophrenia in adults.  The EC based its approval on… Read More

#News #Regulatory

#European Commission #Neuroscience #Otsuka #Schizophrenia

EU approves long-acting injectable for schizophrenia

Abilify Maintena 960mg (aripiprazole) has been approved in the EU as the first once-every- two-months long-acting injectable for the maintenance treatment of schizophrenia. The new long-acting injectable (LAI) formulation enables continuous exposure to medication for two months. Aripiprazole once-every-two-months LAI is a new formulation… Read More

#News #Regulatory

Stamp of approval
#Chemotherapy #European Commission #Leukaemia #Oncology #Otsuka

European Commission approves oral treatment for leukaemia

The European Commission (EC) has approved INAQOVI (oral decitabine and cedazuridine) as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy. INAQOVI, developed by Otsuka Pharmaceutical and Astex Pharmaceuticals, is the first oral hypomethylating… Read More

#News #Regulatory

Dementia
#Alzheimer's #Dementia #FDA #Lundbeck #Otsuka #Phase III trial

FDA approves first drug for agitation due Alzheimer’s dementia

Otsuka and Lundbeck’s Rexulti (brexpiprazole) has become the first pharmacological treatment to be approved in the US for agitation associated with dementia due to Alzheimer’s disease. The Food and Drug Administration (FDA) has approved the companies’ supplemental New Drug Application (sNDA). Agitation is a… Read More

#News #Regulatory